Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

95.41 +0.25 (+0.26%)

Streaming Delayed Price Updated: 10:39 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge

January 02, 2026

As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a...

Via MarketMinute

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Is IonQ Stock a Buy Now? ↗

December 30, 2025

This rising star in quantum computing is a high-risk but potentially high-reward play.

Via The Motley Fool

The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗

December 29, 2025

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands."

Via The Motley Fool

AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗

December 23, 2025

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

Via Chartmill

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Topics Economy Intellectual Property

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗

December 18, 2025

The stocks listed here trade at forward earnings multiples of less than 18.

Via The Motley Fool

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

What to Watch With IonQ Stock in 2026 ↗

December 11, 2025

The New Year is shaping up to be an important one for this quantum computing stock.

Via The Motley Fool

Topics Artificial Intelligence

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗

November 25, 2025

AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation.

Via Chartmill

Why AstraZeneca Stock Bumped Higher Today ↗

November 21, 2025

The company is wasting little time figuring out the particulars of a sweeping capital investment program.

Via The Motley Fool

Topics Artificial Intelligence

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗

November 20, 2025

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data.

Via Benzinga

Where Will IonQ Be in 10 Years? ↗

November 20, 2025

A lot can happen for this quantum computing leader over the next decade.

Via The Motley Fool

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗

November 17, 2025

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Via Investor's Business Daily

IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race

November 14, 2025

November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an...

Via MarketMinute

Topics Intellectual Property

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Why AstraZeneca Stock Was a Winner Today ↗

November 10, 2025

The company inches closer to bringing a new drug to a very large addressable market.

Via The Motley Fool

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial ↗

November 10, 2025

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.

Via Benzinga

3 Reasons to Buy IonQ Stock Like There's No Tomorrow ↗

November 08, 2025

This quantum computing pioneer has tremendous potential.

Via The Motley Fool

Topics Artificial Intelligence Fraud

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Why AstraZeneca Stock Topped the Market on Thursday ↗

November 06, 2025

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

Via The Motley Fool

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗

November 06, 2025

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto...

Via Benzinga

Topics Artificial Intelligence

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable ↗

November 06, 2025

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 guidance reaffirmed.

Via Benzinga

AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar ↗

November 06, 2025

AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.